CAPR - Earnings announcements

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soonHOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpointsGMP manufacturing facility fully operational; second-floor expansion well underway Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks Filed suit against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. seeking rescission of U.S. distribution agreement and preliminary injunction; FDA review and PDUFA date unaffectedCash balance of approximately $279 million expected to support ope

– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the market close on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day. Title:Capricor Therapeutics First Quarter 2026 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, May 12, 2026Time:4:30 p.m. ETCall Details:Toll-Free: 1-80

– Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET – SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day. Title:Capricor Therapeutics Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update Conference Call and Webcast  Date:Thursday, March 12, 2026

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively)Statistical significance was achieved in all type 1 error controlled secondary endpoints Results demonstrate clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential first-in-class therapy designed to treat Duchenne cardiomyopathy, the leading cause of mortality in DuchenneDeramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experienceCompany plans to submit i

Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025)Pending the results of the topline data from the HOPE-3 study, the Company expects to resubmit its BLA, leveraging the data in support of its application for approvalCommercial launch preparations underway to support potential approval and market introduction of Deramiocel in 2026NIAID-sponsored Phase 1 clinical trial underway with StealthX™ exosome-based vaccine; initial topline data currently expected in the first quarter of 2026, subject to completion by NIAIDCash balance of approximately $99 million expected to support planned oper

SAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2025, after the market close on Monday, November 10, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on the same day. Title:Capricor Therapeutics Third Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Monday, November 10, 2025Time:4:30 p.m. ETCall Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference

FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmissionCompany preparing to resubmit CRL response under the current BLAConference call and webcast scheduled for today at 8:30 a.m. ET SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced a regulatory update for its Biologics License Application (BLA) for Deramiocel, the Company's investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). This update follows a rece

Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially serving as supportive and confirmatory evidence, pending regulatory guidanceAll 483 observations noted in the Pre-License Inspection have been resolved and accepted by the FDAFDA clears IND for StealthX™ exosome-based vaccine; NIAID has initiated the Phase 1 clinical trial Cash balance of approximately $123 million expected to support planned operations into the fourth quarter of 2026 Capricor will host a conference call and webcast today at 4:30 p.m. ET SAN DIEGO, Aug. 1

SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the regulatory path for its Biologics License Application (BLA) for Deramiocel, the Company's lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). To accommodate this meeting, the Company has rescheduled the release of its financial results for the second quarter ended June 30, 2025, to Monday, August 11, 2025,

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the market close on Wednesday, August 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on the same day. Title:Capricor Therapeutics Second Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, August 13, 2025Time:4:30 p.m. ETCall Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Confere

FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial in Q3 2025 to continue pursuing the indication for the treatment of cardiomyopathy associated with Duchenne muscular dystrophyFDA advised Capricor to request a meeting to determine next steps toward potential approvalConference call and webcast scheduled for today at 8:30 a.m. ET SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Admini

Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025Recently completed mid-cycle review meeting with FDA with no significant deficiencies identified; late cycle meeting scheduled for June FDA has indicated intent to convene advisory committee meetingAppointed Dr. Michael Binks as Chief Medical Officer, bringing deep experience in neuromuscular and rare diseasesThe National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor's StealthX™ exosome vaccine in the

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, May 13, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 73741Participants can use g

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the fourth quarter and full year ended December 31, 2024, after the market close on Wednesday, March 19, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on March 19. Title:Capricor Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, March 19, 2025Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-18

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on November 13. Title:Capricor Therapeutics Third Quarter 2024 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, November 13, 2024Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 680

-BLA to be Supported by Existing and Natural History Cardiac Data as Discussed with the FDA- -Initial Label Would Include All Patients with Cardiomyopathy Associated with Duchenne Muscular Dystrophy- -Rolling Submission Planned to Commence in October 2024- -Internal GMP Manufacturing Established to Support BLA and Commercialization- -Investor Webcast Today at 8:30 a.m. ET- SAN DIEGO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today, following recent meetings with the U.S. Food and Drug Administration (FDA), its intent to file

SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will host an investor webcast on Tuesday, September 24, 2024 at 8:30 a.m. ET to provide an update on its Duchenne muscular dystrophy (DMD) program. The update will consist of the latest regulatory updates following the Company's recent meetings with the U.S. Food and Drug Administration (FDA). Webcast Details Capricor will host a conference call and webcast at 8:30 a.m. ET on Tuesday, September 24, 2024. To participate in the conference call, please dial 1-800-71

-Recently Held Positive Pre-BLA Meeting with FDA with Aim to Accelerate Approval Pathway of Deramiocel for the Treatment of Duchenne Muscular Dystrophy- -Phase 3, HOPE-3 Trial of Deramiocel in DMD Fully Enrolled; On Track to Report Top-Line Data from Cohort A in Q4 2024- -Reported Positive 3-Year Skeletal and Cardiac Data from HOPE-2 Open-Label Extension Trial- -Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the second quarter ended June 3

-Company to Host Conference Call, August 7, 2024 at 4:30 p.m. ET- SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the second quarter ended June 30, 2024, after the market close on Wednesday, August 7, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on August 7.   Title:Capricor Therapeutics Second Quarter 2024 Financial Results and Recent Corporate Update Conference Call and Webcast  Date:Wednesday, August 7, 2024  Time:4:30 p.m. ET  Conference Call Details:Toll-Free:

–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024– –Positive Type-B CMC FDA Meeting held in Q1; Company Aligned with FDA on Demonstration of Non-Clinical Comparability, A Major Milestone on Path to CMC Clearance for BLA– –Received First Milestone Payment of $10 Million under U.S. Distribution and Commercialization Agreement with Nippon Shinyaku in Q1– –Recent FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission at Upcoming Type-B Clinical FDA Meeting in May 2024– –Plan to Report 3-Year Data from HOPE-2 Open-Label Extension (OLE) Trial in Q2 2024– –Conference Call

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2024, after the market close on Monday, May 13, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Quarter 2024 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Monday, May 13, 2024Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-888-886-7786International: 1-416-764-8658Conference ID: 01529679Participants can use

-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting- -Company Granted Subsequent Type-B Clinical Meeting with FDA in Second Quarter to Continue to Discuss Pathway to BLA- -Capricor Management to Host Virtual Investor Webcast to Discuss Latest Program Updates on Monday, April 29 at 8:30 a.m. ET- SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the tr

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, will release its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Thursday, February 29, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on February 29. Title:Capricor Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update Conference Call and Webcast  Date:Thursday, February 29, 2024  Time:4:30 p.m. ET  Conference Call Details:Toll-Free: 1-888-886

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 14, 2023. Management will then host a webcast and conference call at 4:30 p.m. ET on November 14. Title:Capricor Therapeutics Third Quarter 2023 Financial Results and Recent Corporate Update Conference Call and Webcast  Date:Tuesday, November 14, 2023  Time:4:30 p.m. ET  Conference Call Details:Toll-Free: 1-88

-FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002's Path Towards a Biologics License Application (BLA)- -Company On Track to Complete HOPE-3 Enrollment and Report Outcome from Interim Analysis in Q4 2023- -Conference Call and Webcast Today at 8:30 a.m. ET- SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced an update on the Company's positive Type-B clinical meeting with the U.S. Food and Drug Administration ("FDA") on the desig

-Presented Statistically Significant 24-Month HOPE-2 Open Label Extension Data at the PPMD Annual Conference- -Enrollment Continues to Progress in HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; On Track to Complete Enrollment and Report Interim Analysis in Fourth Quarter of 2023- -Held Type-B Clinical Meeting with the FDA to Discuss CAP-1002's Pathway Towards Potential Biologics License Application Submission- -Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) --  Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the t

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the second quarter ended June 30, 2023, after the market close on Monday, August 7, 2023. Management will then host a webcast and conference call at 4:30 p.m. ET on August 7. Title:Capricor Therapeutics Second Quarter 2023 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Monday, August 7, 2023Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-888-886-7786Internation

-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); On Track to Report Interim Analysis in Fourth Quarter of 2023- -Plan to Present 24-Month HOPE-2 Open Label Extension Data in Second Quarter of 2023- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the first quarter ended March 31, 2023 and provided a corporate

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 11, 2023. Management will then host a webcast and conference call at 4:30 p.m. ET on May 11. Title:Capricor Therapeutics First Quarter 2023 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Thursday, May 11, 2023Time:4:30 p.m. ETConference Call Details:Toll-Free: 1-855-327-6837International

-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); Plan to Report on Interim Analysis in Q4 2023- -Held Type-B CMC Meeting with U.S. Food and Drug Administration (FDA) Regarding Pathway Towards Biologics License Application (BLA) for CAP-1002 in DMD- -Expanded Partnership with Nippon Shinyaku to Japan to Leverage Commercial DMD Franchise with $12 Million Upfront and Additional Potential Milestone Payments of up to $89 Million- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the developme

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the fourth quarter and full year ended December 31, 2022, after the market close on Wednesday, March 15, 2023. Management will then host a webcast and conference call at 4:30 p.m. ET on March 15. Title:Capricor Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, March 15, 2023Time:4:30 p.m. ETConference Call Detai

-Enrollment Continues to Progress in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Presented Positive One-Year Safety and Efficacy Results From HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients at World Muscle Society 2022- -Presented New Advances in Engineered Exosome Platform at Exosome-Based Therapeutic Development Summit- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of musc

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the third quarter ended September 30, 2022, after the market close on Thursday, November 10, 2022. Management will then host a webcast and conference call at 4:30 p.m. ET on November 10. Title:Capricor Therapeutics Third Quarter 2022 Financial Results and Recent Corporate Update Conference Call and Webcast  Date:Thursday, November 10, 2022  Time:4:30 p.m. ET  Conference Call Details:Toll-Free: 1-8

-First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Positive One-Year Safety and Efficacy Results From HOPE-2 Open Label Extension Study of CAP-1002 in Non-Ambulant Duchenne Muscular Dystrophy Patients Presented at PPMD's 2022 Annual Conference- -Requesting Meeting with FDA to Discuss Next Steps in Development of CAP-1002 for Duchenne Muscular Dystrophy- -Pipeline Expansion Underway Using Engineered Exosomes- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- C

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the second quarter ended June 30, 2022, after the market close on Wednesday, August 10, 2022. Management will then host a webcast and conference call at 4:30 p.m. ET on August 10. Title:Capricor Therapeutics Second Quarter 2022 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Wednesday, August 10, 2022Time:4:30 p.m. ETConference Call Details:Toll-Free: 800-289-0571Inte

-Met Primary Endpoint of Performance of the Upper Limb PUL 2.0 (p=0.02)- -Results Suggest Disease Modification in DMD and Long-term Safety of CAP-1002- -Results were Presented at Late Breaking Session at PPMD's Annual Conference on Saturday June 25, 2022- -Principal Investigator Dr. Craig McDonald and Capricor Management Will Host Conference Call and Webcast Today at 8:00 a.m. ET- SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced positive one-year results from its

-Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in the United States- -Upfront Payment of $30 Million Received in 1st Quarter Strengthens Cash Position and Extends Cash Runway- -Positive Phase 2 Results Published in The Lancet Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy- -Pivotal Phase 3 Trial Expecting to Begin Enrolling Patients this Quarter- -Pipeline Expansion Underway Using Engineered Exosomes- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the first quarter ended March 31, 2022, after the market close on Tuesday, May 10, 2022. Management will then host a webcast and conference call at 4:30 p.m. ET on May 10.    Title: Capricor Therapeutics First Quarter 2022 Financial Results and Recent Corporate Update Conference Call and Webcast   Date: Tuesday, May 10, 2022   Time: 4:30 p.m. ET   Conference Call Details: Toll-Free: 888-256-1007Internati

CAP-1002 Cell Therapy Programs -Pivotal Phase 3, HOPE-3 Trial Initiation Underway- -Entered Exclusive Partnership with Nippon Shinyaku for Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in United States- -Capricor to Receive Upfront Payment of $30 Million with Additional Milestone Payments of up to $705 Million- -Phase 2 INSPIRE Top-Line Data Expected by End of First Quarter of 2022- Engineered Exosomes Platform -Pipeline Expansion Underway Using Engineered Exosomes- -Expansion of Senior Leadership Team and Research Facilities in San Diego, California- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, March 10,

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the fourth quarter and full year ended December 31, 2021, after the market close on Thursday, March 10, 2022. Management will then host a webcast and conference call at 4:30 p.m. ET on March 10. Title:Capricor Therapeutics Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Thursday, March 10, 2022Time:4:30 p.m. ETConference Call Details:Toll-

CAP-1002 – Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy-Phase 3 Pivotal Study Cleared to Proceed--Presented Positive Phase 2 HOPE-2 Data at Late-Breaking Oral Presentation at the World Muscle Society Annual Meeting--Met Primary Efficacy Endpoint of Mid Performance of Upper Limb (PUL) v1.2 (p=0.01)- CAP-1002 – Capricor's Cell Therapy Program for COVID-19 -Phase 2 INSPIRE Trial Enrollment Complete with 63 Patients Randomized- Capricor's Engineered Exosomes Platform Technology-Completing Non-Clinical Studies for IND Submission--Pipeline Expansion Underway Using Engineered Exosomes--To Host Conference Call and Webcast Today at 4:30 p.m. ET- SAN DIEGO, Nov. 09, 2021 (GLOBE

LOS ANGELES, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the third quarter ended September 30, 2021, after the market close on Tuesday, November 9, 2021. Management will then host a webcast and conference call at 4:30 p.m. ET on November 9. Title:Capricor Therapeutics Third Quarter 2021 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, November 9, 2021Time:4:30 p.m. ETConferenceCallDetails:Toll-Free: 877-451-6152Inter

–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)– –Additional Positive Endpoints of Full PUL v2.0 (p=0.04) and Cardiac Endpoint of Ejection Fraction (p=0.002)– –One-Year Results Demonstrated CAP-1002 Slowed Decline by 71% (Mid-level PUL v1.2)– –CAP-1002 Significantly Improved Cardiac Function in Patients– –Results Presented Today at World Muscle Society Annual Meeting in Late Breaking Oral Presentation– –Principal Investigator Dr. Craig McDonald and Capricor Management Team will Host a Conference Call and Webcast Today at 8:30 a.m. ET– LOS ANGELES, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) ("Capricor" or

CAP-1002 – Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Following FDA Guidance--Commencing Start-Up Activities for Pivotal Trial--Phase II, HOPE-2 Final Data Submitted for Publication- CAP-1002 – Capricor's Cell Therapy Program for COVID-19 -Phase II INSPIRE Trial Enrollment Nearing Completion- Capricor's Exosomes Platform Technology-Positioning Multivalent Exosome-mRNA Vaccine as Booster to Currently Available Vaccines- -Completing Non-Clinical Studies for IND Submission- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- LOS ANGELES, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechn

LOS ANGELES, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the second quarter ended June 30, 2021, after the market close on Thursday August 12, 2021. Management will then host a webcast and conference call at 4:30 p.m. ET on August 12. Title:Capricor Therapeutics Second Quarter 2021 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Thursday, August 12, 2021Time:4:30 p.m. ETConference CallDetails:Toll-Free: 866-269-4264Internationa